Sugi Predict

Sugi Predict / Compounds / Lenrispodun

Lenrispodun

Lenrispodun

SCHEMBL10201342

CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 20/20 1.00
▸ PDE2A O00408 3/20 0.93
▸ PDE8A O60658 3/20 0.93
▸ PDE5A O76074 3/20 0.93
▸ PDE3B Q13370 3/20 0.93
▸ PDE11A Q9HCR9 3/20 0.93
▸ PDE7B Q9NP56 3/20 0.93
▸ PDE10A Q9Y233 3/20 0.93
▸ PDE9A O76083 2/20 0.93
▸ PDE1B Q01064 1/20 0.93
▸ PDE4B Q07343 1/20 0.93
▸ PDE4C Q08493 1/20 0.93
▸ PDE4D Q08499 1/20 0.93

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lenrispodun SCHEMBL18771113 1.00 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL18211963 1.00 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL29415040 1.00 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL16324627 1.00 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
SCHEMBL20341393 0.98 PDE4A (0.97) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL23610593 0.96 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL21225678 0.96 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL30357428 0.96 PDE4A (1.00) PDE4APDE2APDE8APDE5APDE3B
Lenrispodun SCHEMBL17766669 0.96 PDE4A (0.92) PDE4APDE2APDE8APDE5APDE3B
SCHEMBL8060473 0.94 PDE4A (0.88) PDE4APDE2APDE8APDE5APDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605384-B2 Uses INTRA-CELLULAR THERAPIES, INC. (US) 2026-04-21 — — US claimed
EP-3746081-B1 PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY INTRA CELLULAR THERAPIES INC (US) 2026-04-01 — — EP claimed
US-12435093-B2 Free base crystals INTRA-CELLULAR THERAPIES, INC. (US) 2025-10-07 — — US claimed
US-20250144029-A1 NOVEL COMPOSITIONS INTRA-CELLULAR THERAPIES, INC. (US) 2025-05-08 — — US claimed
US-20250129087-A1 SALT CRYSTALS INTRA-CELLULAR THERAPIES, INC. (US) 2025-04-24 — — US claimed
EP-4472638-A2 SALT CRYSTALS Intra-Cellular Therapies, Inc. (US) 2024-12-11 — — EP claimed
EP-4469052-A1 NOVEL COMPOSITIONS Intra-Cellular Therapies, Inc. (US) 2024-12-04 — — EP claimed
US-20240383909-A1 CO-CRYSTALS INTRA-CELLULAR THERAPIES, INC. 2024-11-21 — — US claimed
EP-4395767-A2 CO-CRYSTALS Intra-Cellular Therapies, Inc. (US) 2024-07-10 — — EP claimed
US-20230338385-A1 NOVEL USES INTRA-CELLULAR THERAPIES, INC. 2023-10-26 — — US claimed
US-9630971-B2 Free base crystals INTRA-CELLULAR THERAPIES, INC. (US) 2017-04-25 — — US claimed
US-20160324860-A1 PRODUCTS AND PHARMACEUTICAL COMPOSITIONS INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-10 — — US claimed
US-9469647-B2 Salt crystals INTRA-CELLULAR THERAPIES, INC. 2016-10-18 — — US claimed
US-20160145261-A1 FREE BASE CRYSTALS INTRA-CELLULAR THERAPIES, INC. (US) 2016-05-26 — — US claimed
EP-3010509-A2 FREE BASE CRYSTALS Intra-Cellular Therapies, Inc. (US) 2016-04-27 — — EP claimed
US-20150259353-A1 SALT CRYSTALS INTRA-CELLULAR THERAPIES, INC. 2015-09-17 — — US claimed
WO-2014205354-A2 FREE BASE CRYSTALS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-24 — — WO claimed
US-8829008-B2 Organic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-09 — — US claimed
US-8273751-B2 Organic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-09-25 — — US claimed
US-20120238589-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2012-09-20 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435093-B2 Free base crystals NT5C3B, NT5C, MTAP PDE4A 741/4885PDE2A 1405/4885PDE8A 820/4885
US-20160145261-A1 FREE BASE CRYSTALS NT5C3B, MTAP, NT5C PDE4A 579/4885PDE2A 1176/4885PDE8A 577/4885
US-20150259353-A1 SALT CRYSTALS REN, SLC28A1, SLC20A1 PDE4A 1589/4885PDE2A 2426/4885PDE8A 954/4885
US-20120238589-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A7 PDE4A 734/4885PDE2A 358/4885PDE8A 1400/4885
US-20250144029-A1 NOVEL COMPOSITIONS SYNCRIP, HNRNPR, PRNP PDE4A 1092/4885PDE2A 947/4885PDE8A 1007/4885
US-20160324860-A1 PRODUCTS AND PHARMACEUTICAL COMPOSITIONS PDE2A, PDE3A, PDE5A PDE4A 6/4885PDE2A 1/4885PDE8A 21/4885
US-20240383909-A1 CO-CRYSTALS NT5C3B, PRNP, MTAP PDE4A 1375/4885PDE2A 1415/4885PDE8A 1607/4885
US-20250129087-A1 SALT CRYSTALS SLC28A1, REN, NT5C3B PDE4A 1525/4885PDE2A 1873/4885PDE8A 766/4885
US-20230338385-A1 NOVEL USES ADORA2A, ATP2A1, ADORA2B PDE4A 11/4885PDE2A 4/4885PDE8A 34/4885
US-12605384-B2 Uses PDE2A, NPR1, PDE7A PDE4A 13/4885PDE2A 1/4885PDE8A 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.